Cystatin C-NT-proBNP Combined Risk Score Calculator

Clinical calculation support · Verify results before clinical use

Biomarker inputs

Enter both laboratory values to view a descriptive, threshold-based summary.

— Markers

Use the measured serum Cystatin C concentration reported by the laboratory.

Use the measured NT-proBNP concentration. Interpretation depends on clinical context, age, renal function, and the reason for testing.

Clinical context

Cystatin C is a marker used to assess kidney function and can provide prognostic information in cardiovascular disease. Its interpretation depends on the assay, kidney function, and the patient population.

NT-proBNP is released in response to myocardial wall stress and is used in the evaluation of suspected heart failure and in prognostic assessment. Values are influenced by factors including age and renal function, and must be interpreted in clinical context.

Studies support the complementary prognostic value of kidney-function measures and natriuretic peptides in selected heart-failure populations. That evidence does not, by itself, validate the simple two-threshold score shown here.

Thresholds retained from the source code

MarkerThreshold used by this toolEvidence status
Cystatin C≥ 1.0 mg/LRetained from the original PHP; not verified as a universal or model-specific cutoff.
NT-proBNP≥ 125 pg/mLA threshold used in some contexts to identify elevated NT-proBNP, but not verified as part of this exact combined score.

How to use the result

  • Review both biomarker values separately alongside symptoms, examination, kidney function, age, and the clinical indication for testing.
  • Do not interpret the marker count as an absolute or relative probability of death, heart failure, or another cardiovascular outcome.
  • Use a validated clinical prediction model or the relevant guideline pathway when a formal risk estimate is needed.

References

Shlipak MG, Matsushita K, Ärnlöv J, et al. Cystatin C versus creatinine in determining risk based on kidney function. New England Journal of Medicine. 2013;369:932–943. DOI: 10.1056/NEJMoa1214234.
Januzzi JL Jr, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. European Heart Journal. 2006;27(3):330–337. DOI: 10.1093/eurheartj/ehi631.
Wang TJ, et al. (reference cited in the original template) The original PHP listed Circulation. 2008;117:2503–2510 and DOI 10.1161/CIRCULATIONAHA.107.738658. The title and its relationship to the exact two-threshold algorithm were not confirmed during this audit; verify the bibliographic record before relying on it as the model source.
Huang Y, et al. Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure. Clinical Cardiology. 2015. PubMed: PMID 25663560. This study evaluated a heart-failure cohort and does not validate the simplified score implemented here.
Clinical disclaimer: This page provides a descriptive threshold count based on the values retained from the original template. It is not a validated risk prediction model, diagnostic instrument, or substitute for clinical judgement. Biomarker thresholds depend on the clinical setting, assay, age, renal function, and intended use. Confirm the appropriate interpretation using current guidance and the laboratory’s reference information.